Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2021 Jun 30

PMID 34189182

Citations 5

Authors

Nicholas Chamberlain

Leandro Mena

James Benjamin Brock

Affiliations

Soon will be listed here.

Abstract

Few instances of treatment-emergent resistance to bictegravir have been reported in the literature. We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with human immunodeficiency virus who developed M184V and R263K mutations while on therapy.

Citing Articles

Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants.

Powis K, Pinilla M, McMorrow F, Stek A, Brooks K, Shapiro D J Acquir Immune Defic Syndr. 2025; 98(3):300-307.

PMID: 39813286 PMC: 11798693. DOI: 10.1097/QAI.0000000000003571.

Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study.

Rolle C, Castano J, Nguyen V, Hinestrosa F, DeJesus E Open Forum Infect Dis. 2024; 11(10):ofae560.

PMID: 39416993 PMC: 11482008. DOI: 10.1093/ofid/ofae560.

2022 update of the drug resistance mutations in HIV-1.

Wensing A, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard H, Paredes R Top Antivir Med. 2022; 30(4):559-574.

PMID: 36375130 PMC: 9681141.

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report.

van Kampen J, Pham H, Yoo S, Overmars R, Lungu C, Mahmud R J Glob Antimicrob Resist. 2022; 31:323-327.

PMID: 36347497 PMC: 10258191. DOI: 10.1016/j.jgar.2022.11.001.

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence .

Acosta R, DAntoni M, Mulato A, Yant S, Cihlar T, White K Antimicrob Agents Chemother. 2022; 66(5):e0203821.

PMID: 35389236 PMC: 9112893. DOI: 10.1128/aac.02038-21.

References

Pena M, Chueca N, DAvolio A, Zarzalejos J, Garcia F . Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. Open Forum Infect Dis. 2019; 6(1):ofy332. PMC: 6324549. DOI: 10.1093/ofid/ofy332. View

Oliveira M, Mesplede T, Quashie P, Moisi D, Wainberg M . Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014; 28(6):813-9. DOI: 10.1097/QAD.0000000000000199. View

Anstett K, Brenner B, Mesplede T, Wainberg M . HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017; 14(1):36. PMC: 5460515. DOI: 10.1186/s12977-017-0360-7. View

Nel A, Kagee A . Common mental health problems and antiretroviral therapy adherence. AIDS Care. 2011; 23(11):1360-5. DOI: 10.1080/09540121.2011.565025. View

Singhroy D, Wainberg M, Mesplede T . Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother. 2015; 59(5):2882-5. PMC: 4394770. DOI: 10.1128/AAC.05181-14. View